about
Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malariaIdentification of minimal human MHC-restricted CD8+ T-cell epitopes within the Plasmodium falciparum circumsporozoite protein (CSP)A glycolipid adjuvant, 7DW8-5, enhances CD8+ T cell responses induced by an adenovirus-vectored malaria vaccine in non-human primatesDiscovery of Novel Plasmodium falciparum Pre-Erythrocytic Antigens for Vaccine DevelopmentProtection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoitesThe RTS,S malaria vaccineCorrection: Modification of Ad5 Hexon Hypervariable Regions Circumvents Pre-Existing Ad5 Neutralizing Antibodies and Induces Protective Immune ResponsesAdenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP componentAdenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adultsA systematic review of safety data reporting in clinical trials of vaccines against malaria, tuberculosis, and human immunodeficiency virus.Assessing the Parasight-F test in northeastern Papua, Indonesia, an area of mixed Plasmodium falciparum and Plasmodium vivax transmission.Tolerability of azithromycin as malaria prophylaxis in adults in northeast papua, indonesia.Plasmodium falciparum. Mechanisms of innate and acquired protection against Plasmodium falciparum in Javanese transmigrant adults and children newly resident in malaria-endemic Northwest Papua.Malaria in a cohort of Javanese migrants to Indonesian Papua.Primary infection by Plasmodium falciparum or P. vivax in a cohort of Javanese migrants to Indonesian Papua.Age-dependent impairment of IgG responses to glycosylphosphatidylinositol with equal exposure to Plasmodium falciparum among Javanese migrants to Papua, Indonesia.Chloroquine-resistant Plasmodium vivax in transmigration settlements of West Kalimantan, Indonesia.Mefloquine is highly efficacious against chloroquine-resistant Plasmodium vivax malaria and Plasmodium falciparum malaria in Papua, Indonesia.Protection of rhesus monkeys by a DNA prime/poxvirus boost malaria vaccine depends on optimal DNA priming and inclusion of blood stage antigens.Acquisition of invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein 1 in a transmigrant population requires multiple infections.Changes in the total leukocyte and platelet counts in Papuan and non Papuan adults from northeast Papua infected with acute Plasmodium vivax or uncomplicated Plasmodium falciparum malariaSterile protection against Plasmodium knowlesi in rhesus monkeys from a malaria vaccine: comparison of heterologous prime boost strategies.Boosting of DNA vaccine-elicited gamma interferon responses in humans by exposure to malaria parasites.Using infective mosquitoes to challenge monkeys with Plasmodium knowlesi in malaria vaccine studiesExpression of HLA class II molecules in humanized NOD.Rag1KO.IL2RgcKO mice is critical for development and function of human T and B cells.Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine.Etiology of acute, non-malaria, febrile illnesses in Jayapura, northeastern Papua, Indonesia.Identification and localization of minimal MHC-restricted CD8+ T cell epitopes within the Plasmodium falciparum AMA1 proteinAssociations between responses to the rhoptry-associated membrane antigen of Plasmodium falciparum and immunity to malaria infectionSterile immunity to malaria after DNA prime/adenovirus boost immunization is associated with effector memory CD8+T cells targeting AMA1 class I epitopesModification of Ad5 hexon hypervariable regions circumvents pre-existing Ad5 neutralizing antibodies and induces protective immune responsesRandomised placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria.Humanized HLA-DR4.RagKO.IL2RγcKO.NOD (DRAG) mice sustain the complex vertebrate life cycle of Plasmodium falciparum malariaProtection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine.Progress and challenges for malaria vaccines.Consistent safety and infectivity in sporozoite challenge model of Plasmodium vivax in malaria-naive human volunteers.Immune responses and protection of Aotus monkeys immunized with irradiated Plasmodium vivax sporozoitesDNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity.Vaccines against asexual stage malaria parasites.Haemoglobin dynamics in Papuan and non-Papuan adults in northeast Papua, Indonesia, with acute, uncomplicated vivax or falciparum malaria.
P50
Q21032534-A45BF357-E508-418F-AD4C-D2537BD614A8Q21034050-E14C5931-3344-4A79-8ADF-969BDE44E5DAQ27303293-25CCFD42-7757-4EDD-8AEC-F09D0E571555Q27972709-2BC933E4-C6BD-46C4-9EB2-420DD3519DBBQ28212476-C4ED2BBE-F8B0-463D-9E9F-860DF4449CDAQ28285472-C416D2F4-D851-4D82-BE70-8A8A631678D8Q28730110-45350879-5463-45DD-891A-CB455B37F49DQ28744136-81B2495E-BE95-47DA-BBD5-0308DC6E5D8DQ28744149-FFDA92EE-BBDF-40A5-B173-3002CF299066Q30587522-94E4729A-64E8-408E-846A-339DF6FDB8C4Q30847318-C76610C6-D254-45E2-B64A-671DCF546739Q30951402-A0CEA0F7-5755-47D0-810D-987CA7F1F0E9Q30976175-E5FAD7F3-9579-4D37-B95E-104D210E76BCQ31002444-15B3772C-D064-4625-A6CE-9778DA844CC3Q31002463-E4AE0D7A-8D83-4D48-AB31-1B404012A520Q31154588-4790B15F-0232-4A5A-B86A-5017B8863EE8Q31991100-A3132F82-F573-42F1-B7D3-464378ACCB4CQ33238120-16654923-55FC-45A5-B922-67FD555C95EDQ33303670-A3BDBB1A-3B74-47A9-9BCF-FD5E85EF1F42Q33362115-EB81E932-200C-4FFA-97D8-2828C0BB6C65Q33382509-F0FFA290-941B-42E3-8019-E2449D1B29E9Q33492290-7B9B5934-A16B-4515-99FF-E7EED7DD0F20Q33768911-28B23DCB-20BD-4A9B-9D0F-A94397AE674AQ33805512-D7E4CC50-32D2-4E97-B958-312D9F772344Q33911359-51968447-9CD2-4FC2-9682-5033C0652DF3Q33943869-AC840F1E-0752-4D0B-B48D-519C4E3A5821Q34122576-8AB45780-E7CF-447D-8BE4-FEB3E56B1192Q34128586-E774285B-0982-4391-9FE3-07E839E5B97EQ34145697-8EF211A3-05CF-41BE-B93B-C0FB38012009Q34165879-943046DC-F8A9-46C5-91A8-7834617B9ED5Q34229968-D6295441-F12C-4733-8D6E-4DE438B470D2Q34288516-B0F47D2C-9354-4277-A68D-3799694CF0FCQ34340419-9FBD3F0B-0A39-4FEB-86E8-6D317C5A135FQ34362872-858C1C50-475E-499C-A248-FC4F768A3CF3Q34521010-30A7A438-1910-4829-A724-BE54B8D40574Q34546194-8A269ED0-2DA4-43E8-9673-8D2955D4B2C7Q34546225-DD83D65C-F49F-425F-8CDE-8A65B4A6402BQ34606356-BA97DAC0-F411-4530-9F7F-A0132729C6B1Q34680120-09F2CF2E-6F5A-4B28-8BF3-D22C68B85E6AQ34777441-BFE45A22-5426-4040-BD9E-1CE714AA521E
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Thomas L. Richie
@ast
Thomas L. Richie
@en
Thomas L. Richie
@es
Thomas L. Richie
@nl
Thomas L. Richie
@sl
type
label
Thomas L. Richie
@ast
Thomas L. Richie
@en
Thomas L. Richie
@es
Thomas L. Richie
@nl
Thomas L. Richie
@sl
altLabel
Thomas L Richie
@en
prefLabel
Thomas L. Richie
@ast
Thomas L. Richie
@en
Thomas L. Richie
@es
Thomas L. Richie
@nl
Thomas L. Richie
@sl
P106
P21
P2798
P31
P496
0000-0002-2946-5456